Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Favezelimab/pembrolizumab - Merck Sharp & Dohme

Next Previous
Drug Profile

Favezelimab/pembrolizumab - Merck Sharp & Dohme

Alternative Names: Coformulation favezelimab/pembrolizumab - Merck Sharp & Dohme; Mavezelimab/pembrolizumab - Merck Sharp & Dohme; MK 4280A; MK-4820A; Pembrolizumab/favezelimab - Merck Sharp & Dohme

Latest Information Update: 12 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bladder cancer; Colorectal cancer; Endometrial cancer; Hodgkin's disease; Malignant melanoma; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 18 May 2026 Merck Sharp & Dohmecompletes a phase-I/II clinical trials in Malignant melanoma (Late-stage disease, First-line therapy, Inoperable/Unresectable) in USA, Argentina, Australia, Chile, Colombia, France, Greece, Hungary, Israel, Italy, Poland, South Africa, Spain, Switzerland (IV, Infusion) (NCT04305054)
  • 12 Mar 2026 Merck Sharp & Dohme completes a phase-II clinical trials in Endometrial cancer (Second-line therapy or greater, Late-stage disease, Recurrent, Metastatic disease, Combination Therapy) in Turkey, Netherlands, Malaysia, Italy, Germany, France, Canada, USA (IV) (NCT06036836)
  • 12 Mar 2026 Merck Sharp & Dohme completes a phase-II clinical trials in Endometrial cancer (Second-line therapy or greater, Late-stage disease, Recurrent, Metastatic disease, Monotherapy) in Turkey, Netherlands, Malaysia, Italy, Germany, France, Canada, USA (IV) (NCT06036836)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top